Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Age-Related Maculopathy

In brief

The purpose of this study is to determine the efficacy, safety and tolerability of multiple doses of RN6G in subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration.

Key facts

Study ID
NCT01577381
Run by
Pfizer
People needed
10
Starts
2012-08-01
Expected to finish
2013-10-01
Last updated by the study team
2016-03-16

Who can join

Age: 60 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.